Novel therapeutic strategies for Clostridium difficile infections

Basit Öğe Kaydı
dc.contributor.authorÜnal, Can Murat
dc.contributor.authorSteinert, Michael
dc.date.accessioned2021-01-08T21:51:27Z
dc.date.available2021-01-08T21:51:27Z
dc.date.issued2016
dc.departmentTAÜ, Fen Fakültesi, Moleküler Biyoteknoloji Bölümüen_US
dc.descriptionUnal, Can/0000-0003-4710-9567en_US
dc.descriptionWOS:000370162800001en_US
dc.descriptionPubMed: 26565670en_US
dc.description.abstractIntroduction: In recent years, Clostridium difficile has become the primary cause of antibiotic-associated diarrhea and pseudomembranous colitis, resulting in long and complicated hospital stays that represent a serious burden for patients as well as health care systems. Currently, conservative treatment of C. difficile infection (CDI) relies on the antibiotics vancomycin, metronidazole or fidaxomicin, or in case of multiple recurrences, fecal microbiota transplantation (FMT).Areas covered: The fast-spreading, epidemic nature of this pathogen urgently necessitates the search for alternative treatment strategies as well as antibiotic targets. Accordingly, in this review, we highlight the recent findings regarding virulence associated traits of C. difficile, evaluate their potential as alternative drug targets, and present current efforts in designing inhibitory compounds, with the aim of pointing out possibilities for future treatment strategies.Expert opinion: Increased attention on systematic analysis of the virulence mechanisms of C. difficile has already led to the identification of several alternative drug targets. In the future, applying state of the art omics' and the development of novel infection models that mimic the human gut, a highly complex ecological niche, will unveil the genomic and metabolic plasticity of this pathogen and will certainly help dealing with future challenges.
dc.description.sponsorshipFederal State of Lower Saxony, Niedersachsisches Vorab [VWZN2889]
dc.description.sponsorshipCM Unal and M Steinert were supported in this work by the Federal State of Lower Saxony, Niedersachsisches Vorab (VWZN2889). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
dc.identifier.doi10.1517/14728222.2016.1090428
dc.identifier.endpage285en_US
dc.identifier.issn1472-8222
dc.identifier.issn1744-7631
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-84958044860
dc.identifier.scopusqualityQ1
dc.identifier.startpage269en_US
dc.identifier.urihttp://doi.org/10.1517/14728222.2016.1090428
dc.identifier.urihttps://hdl.handle.net/20.500.12846/270
dc.identifier.volume20en_US
dc.identifier.wosWOS:000370162800001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorÜnal, Can Murat
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofExpert Opinion On Therapeutic Targets
dc.relation.publicationcategoryother
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAlternative Drug Targetsen_US
dc.subjectAntibiotic Resistanceen_US
dc.subjectCdaden_US
dc.subjectC. Difficile Infectionen_US
dc.subjectClostridium Difficileen_US
dc.subjectSmall Inhibitorsen_US
dc.subjectTherapeuticsen_US
dc.subjectToxinsen_US
dc.subjectVirulence Factorsen_US
dc.titleNovel therapeutic strategies for Clostridium difficile infections
dc.typeReview Article

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
00270.pdf
Boyut:
529.33 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Moleküler Biyoteknoloji
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu